This, coupled with the report that inactivating the USP45 protein that deubiquitinates ERCC1 in human myelogenous leukaemia and osteosarcoma cells leads to reduced levels of NER and increased sensitivity to UV irradiation [45], suggests that our therapeutic strategy is likely applicable to a wide range of human cancers. Here, ERCC1 is linked to osteosarcoma.